ALK-positive non-small cell lung cancer (NSCLC) is a subtype of lung cancer characterised by a genetic mutation in the anaplastic lymphoma kinase (ALK) gene. Several first-line treatments are available for this condition, each with its own set of benefits and drawbacks. ALK-positive NSCLC accounts for about 5% of all non-small cell lung cancer cases.
